PEG 3350 的全球市场：按产品类型、使用期限、应用、分销管道和地区进行预测（~2032 年）

PEG 3350市场规模预计将从2023年的19.2亿美元和2024年的20.8亿美元成长到2032年的37.1亿美元，预测期内复合年增长率为6.63%。印度和其他新兴市场的大肠癌盛行率不断上升、策略性举措不断增加、久坐生活方式和缺乏身体活动的情况日益增多，推动了市场成长。

大肠直肠癌在全世界不断增加。例如，根据Lancet Regional Health Southeast Asia的一篇论文，大肠直肠癌是印度第七大流行癌症，2021 年新增病例为 65,358 例。全球大肠直肠癌发生率呈上升趋势，目前大肠癌发生率为每10万人19.5例，印度每10万人15.2例。另一个影响因素是生活方式的演变，包括高热量和低膳食纤维的饮食、过量摄取红肉和加工食品以及缺乏运动。此外，印度年龄-性别调整后的大肠癌发生率增加了20.6%，其中50岁以下成年人的数量显着增加。

考虑到这些因素，随着大肠癌盛行率的增加，对 PEG 3350 的需求预计将会增加。据预测，除了大肠直肠癌的累积盛行率外，PEG 3350市场预计还将受到生活方式变化的推动，例如预测期内酒精和烟草产品消费的增加、吸烟率的上升以及不良的饮食习惯。

区域展望

2022年，北美PEG 3350市场占据最高市场份额。这是北美地区大肠直肠癌和糖尿病、癌症和神经病变等其他疾病盛行率不断上升的结果。

欧洲市场的份额位居第二，这归因于大肠癌盛行率的不断上升以及该地区久坐生活方式的日益普及。此外，德国的PEG 3350市场被认为拥有最大的市场份额，预计将成为欧洲地区成长最快的市场。

预计2024年至2032年亚太地区市场将大幅成长。这是该地区大肠癌盛行率不断上升、久坐的生活方式和缺乏体力活动以及老年人口不断增长的结果。按国家划分，预计中国所占份额最高，其次是印度。

该报告调查了全球PEG 3350 市场，并提供了市场定义和概述、影响市场成长和市场机会的因素分析、市场规模趋势和预测、按各个区隔市场/地区/主要国家进行的区隔，总结了竞争环境、主要市场概况公司等

目录

第1章 内容提要

第2章 市场概况

第3章 研究方法

第4章 市场动态

• 概述
• 促进因素
  • 印度和其他发展中国家的大肠癌发生率不断上升
  • 增加策略举措
  • 久坐生活方式的增加和缺乏运动
• 抑制因素
  • 与 PEG 相关的副作用
  • 人们越来越偏爱有机替代品
• 机会
  • 进军新兴市场

第5章 市场因素分析

• 价值链分析
• 波特五力分析
• COVID-19对全球PEG 3350市场的影响

第六章全球 PEG 3350 市场：依产品类型

• 概述
• 粉末
• 肠道预处理套件

第七章全球 PEG 3350 市场：依年龄分类

• 概述
• 孩子
• 成人
• 老年人

第八章全球 PEG 3350 市场：依应用分类

• 概述
• 便秘
• 医学测试
  • 大肠镜检查
  • 钡剂灌肠X光检查
• 手术

第9章全球PEG 3350市场：按分销管道

• 概述
• 网上药店
• 线下药局

第10章全球PEG 3350市场：按地区

• 概述
• 北美
• 欧洲
• 亚太地区
• 其他地区

第11章 竞争格局

• 概述
• 竞争标桿
• 全球 PEG 3350 市场的主要成长策略
• 全球 PEG 3350 市场开发数量领先的公司
• 主要发展和成长策略

第12章 公司简介

• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• LGM PHARMA
• MCKESSON CORPORATION
• SISCO RESEARCH LABORATORIES PVT. LTD.
• BASF SE
• MERCK KGAA
• BAYER AG
• LUPIN PHARMACEUTICALS, INC.
• BRECKENRIDGE PHARMACEUTICAL, INC.
• PENDOPHARM

第13章 附录

Global PEG 3350 Market Research Report Information by Product Type (Powder, Bowel Preparation Kit) by Age (Pediatric, Adult, and Geriatric) by Application (Constipation, Medical Tests, [Colonoscopy and Barium Enema X-Ray Examination], and Surgery) by Distribution Channel (Online Pharmacy, Offline Pharmacy), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview

In 2023, the market size of PEG 3350 was estimated to be USD 1.92 billion. During the forecast period (2024-2032), the PEG 3350 Market industry is anticipated to experience a compound annual growth rate (CAGR) of 6.63%, increasing from USD 2.08 billion in 2024 to USD 3.71 billion by 2032. The market growth is being driven by the increasing prevalence of colon cancer in India and other developing nations, the increasing number of strategic initiatives, and the increasing sedentary lifestyle and physical inactivity.

Colon cancer is becoming more prevalent on a global scale. For example, the Lancet Regional Health Southeast Asia article indicates that colorectal cancer is the seventh most prevalent cancer in India, with 65,358 new cases in 2021. The global incidence of colon cancer has been on the rise, with a current rate of 19.5 per 100,000 population and 15.2 per 100,000 population in India. In the same vein, the evolving lifestyles that encompass the consumption of calorie-rich and low-fiber diets, the excessive consumption of red meat and processed foods, and physical inactivity. Additionally, the age-sex-adjusted rates of colon cancer in India have increased by 20.6%, with a significant increase in the number of adults under the age of 50.

Consequently, the demand for PEG 3350 is expected to rise in response to the increasing prevalence of colon cancer. The PEG 3350 markets are anticipated to be driven by the cumulative prevalence of colon cancer, as well as changing lifestyle habits, including the increasing consumption of alcohol and tobacco products, the rising rates of smoking, and poor dietary habits among the population, during the forecast period.

Market Segment Insights

Powder and digestive preparation kit-based market segmentation for the PEG 3350.

Age is the basis for market segmentation, which encompasses pediatric, adult, and geriatric categories.

The PEG 3350 Market segmentation is determined by the application, which encompasses medical tests and constipation. and surgery.

The market segmentation is determined by the distribution channels, which encompass both online and offline pharmacies.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2022, the North American PEG 3350 market held the highest market share. This is a result of the increasing prevalence of colorectal cancer and other diseases, including diabetes, cancer, and neurological disorders, in the North American region.

The second-largest market share in the Europe PEG 3350 market is attributed to the increasing prevalence of colorectal cancer and the increasing adoption of a sedentary lifestyle throughout the region. In addition, the German PEG 3350 Market was identified as the greatest market share and is anticipated to be the fastest-growing market in the European region.

It is anticipated that the Asia-Pacific PEG 3350 market will experience substantial growth from 2024 to 2032. This is a result of the increasing prevalence of colorectal cancer in the Asia-Pacific region, the adoption of sedentary lifestyles and physical inactivity, and the growing geriatric population. Additionally, it is anticipated that the China PEG 3350 Market will possess the highest market share, while India is anticipated to follow suit. The PEG 3350 Market is anticipated to be the fastest-growing market in the Asia-Pacific region.

The Middle East, Africa, and Latin America comprise the Rest of the World. The PEG 3350 Market in the regions is expected to experience growth as a result of the lack of awareness associated with the appropriate diet. Additionally, the research indicates that colorectal cancer is on the rise in the Middle East among young and older individuals, and it is a primary cause of frequent constipation in children, which is further contributing to the region's market growth.

Major Players

Teva Pharmaceutical Industries Ltd (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), Merck KGaA (US), Bayer AG (Germany), Lupin Pharmaceuticals, Inc (India), Breckenridge Pharmaceutical, Inc. (US), and Pendopharm (Canada) are among the key companies in the PEG 3350 Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 RISING PREVALENCE OF COLON CANCER IN INDIA AND OTHER DEVELOPING NATIONS
  • 4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES
  • 4.2.3 INCREASING SEDENTARY LIFESTYLE AND PHYSICAL INACTIVITY
• 4.3 RESTRAINTS
  • 4.3.1 SIDE EFFECTS ASSOCIATED WITH PEG
  • 4.3.2 INCREASING PREFERENCE FOR ORGANIC ALTERNATIVES
• 4.4 OPPORTUNITIES
  • 4.4.1 ENTERING DEVELOPING MARKETS

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION
  • 5.1.4 MARKETING & SALES
  • 5.1.5 POST-SALES REVIEW/MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL PEG 3350 MARKET
  • 5.3.1 IMPACT ON DEMAND
  • 5.3.2 IMPACT ON SUPPLY CHAIN
  • 5.3.3 IMPACT ON MARKET PLAYERS

6 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE

• 6.1 OVERVIEW
• 6.2 POWDER
• 6.3 BOWEL PREPARATION KIT

7 GLOBAL PEG 3350 MARKET, BY AGE

• 7.1 OVERVIEW
• 7.2 PEDIATRIC
• 7.3 ADULT
• 7.4 GERIATRIC

8 GLOBAL PEG 3350 MARKET, BY APPLICATION

• 8.1 OVERVIEW
• 8.2 CONSTIPATION
• 8.3 MEDICAL TESTS
  • 8.3.1 COLONOSCOPY
  • 8.3.2 BARIUM ENEMA X-RAY EXAMINATION
• 8.4 SURGERY

9 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL

• 9.1 OVERVIEW
• 9.2 ONLINE PHARMACY
• 9.3 OFFLINE PHARMACY

10 GLOBAL PEG 3350 MARKET, BY REGION

• 10.1 OVERVIEW
• 10.2 NORTH AMERICA
  • 10.2.1 US
  • 10.2.2 CANADA
• 10.3 EUROPE
  • 10.3.1 GERMANY
  • 10.3.2 FRANCE
  • 10.3.3 UK
  • 10.3.4 ITALY
  • 10.3.5 SPAIN
  • 10.3.6 REST OF EUROPE
• 10.4 ASIA-PACIFIC
  • 10.4.1 CHINA
  • 10.4.2 INDIA
  • 10.4.3 JAPAN
  • 10.4.4 SOUTH KOREA
  • 10.4.5 AUSTRALIA
  • 10.4.6 REST OF ASIA-PACIFIC
• 10.5 REST OF THE WORLD
  • 10.5.1 MIDDLE EAST
  • 10.5.2 AFRICA
  • 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 COMPETITIVE BENCHMARKING
• 11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL PEG 3350 MARKET
• 11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL PEG 3350 MARKET
• 11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 11.5.1 PRODUCT LAUNCH/PRODUCT APPROVAL

12 COMPANY PROFILES

• 12.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 12.1.1 COMPANY OVERVIEW
  • 12.1.2 FINANCIAL ANALYSIS
  • 12.1.3 PRODUCTS/SERVICES OFFERED
  • 12.1.4 KEY DEVELOPMENTS
  • 12.1.5 KEY STRATEGIES
• 12.2 LGM PHARMA
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 FINANCIAL OVERVIEW
  • 12.2.3 PRODUCTS/SERVICES OFFERED
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 KEY STRATEGIES
• 12.3 MCKESSON CORPORATION
  • 12.3.1 COMPANY OVERVIEW
  • 12.3.2 FINANCIAL OVERVIEW
  • 12.3.3 PRODUCTS/SERVICES OFFERED
  • 12.3.4 KEY DEVELOPMENTS
  • 12.3.5 SWOT ANALYSIS
  • 12.3.6 KEY STRATEGIES
• 12.4 SISCO RESEARCH LABORATORIES PVT. LTD.
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 FINANCIAL OVERVIEW
  • 12.4.3 PRODUCTS/SERVICES OFFERED
  • 12.4.4 KEY DEVELOPMENTS
  • 12.4.5 KEY STRATEGIES
• 12.5 BASF SE
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 FINANCIAL OVERVIEW
  • 12.5.3 PRODUCTS/SERVICES OFFERED
  • 12.5.4 KEY DEVELOPMENTS
  • 12.5.5 SWOT ANALYSIS
  • 12.5.6 KEY STRATEGIES
• 12.6 MERCK KGAA
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 FINANCIAL OVERVIEW
  • 12.6.3 PRODUCTS OFFERED
  • 12.6.4 KEY DEVELOPMENTS
  • 12.6.5 SWOT ANALYSIS
  • 12.6.6 KEY STRATEGIES
• 12.7 BAYER AG
  • 12.7.1 COMPANY OVERVIEW
  • 12.7.2 FINANCIAL OVERVIEW
  • 12.7.3 PRODUCTS OFFERED
  • 12.7.4 KEY DEVELOPMENTS
  • 12.7.5 SWOT ANALYSIS
  • 12.7.6 KEY STRATEGIES
• 12.8 LUPIN PHARMACEUTICALS, INC.
  • 12.8.1 COMPANY OVERVIEW
  • 12.8.2 FINANCIAL OVERVIEW
  • 12.8.3 PRODUCTS OFFERED
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 SWOT ANALYSIS
  • 12.8.6 KEY STRATEGIES
• 12.9 BRECKENRIDGE PHARMACEUTICAL, INC.
  • 12.9.1 COMPANY OVERVIEW
  • 12.9.2 FINANCIAL OVERVIEW
  • 12.9.3 PRODUCTS OFFERED
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 KEY STRATEGIES
• 12.10 PENDOPHARM
  • 12.10.1 COMPANY OVERVIEW
  • 12.10.2 FINANCIAL OVERVIEW
  • 12.10.3 PRODUCTS OFFERED
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 KEY STRATEGIES

13 APPENDIX

• 13.1 REFERENCES
• 13.2 RELATED REPORTS

LIST OF TABLES

• TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
• TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
• TABLE 3 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 4 GLOBAL PEG 3350 MARKET, FOR POWDER, BY REGION, 2019-2032 (USD BILLION)
• TABLE 5 GLOBAL PEG 3350 MARKET, FOR BOWEL PREPARATION KIT, BY REGION, 2019-2032 (USD BILLION)
• TABLE 6 GLOBAL PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 7 GLOBAL PEG 3350 MARKET, FOR PEDIATRIC, BY REGION, 2019-2032 (USD BILLION)
• TABLE 8 GLOBAL PEG 3350 MARKET, FOR ADULT, BY REGION, 2019-2032 (USD BILLION)
• TABLE 9 GLOBAL PEG 3350 MARKET, FOR GERIATRIC, BY REGION, 2019-2032 (USD BILLION)
• TABLE 10 GLOBAL PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 11 GLOBAL PEG 3350 MARKET, FOR CONSTIPATION, BY REGION, 2019-2032 (USD BILLION)
• TABLE 12 GLOBAL PEG 3350 MARKET, FOR MEDICAL TESTS, BY REGION, 2019-2032 (USD BILLION)
• TABLE 13 GLOBAL PEG 3350 MARKET, FOR COLONOSCOPY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 14 GLOBAL PEG 3350 MARKET, FOR BARIUM ENEMA X-RAY EXAMINATION, BY REGION, 2019-2032 (USD BILLION)
• TABLE 15 GLOBAL PEG 3350 MARKET, FOR SURGERY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 16 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 17 GLOBAL PEG 3350 MARKET, FOR ONLINE PHARMACY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 18 GLOBAL PEG 3350 MARKET, FOR OFFLINE PHARMACY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 19 GLOBAL: PEG 3350 MARKET, BY REGION, 2019-2032 (USD BILLION)
• TABLE 20 NORTH AMERICA: PEG 3350 MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
• TABLE 21 NORTH AMERICA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 22 NORTH AMERICA: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 23 NORTH AMERICA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 24 NORTH AMERICA: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2019-2032 (USD BILLION)
• TABLE 25 NORTH AMERICA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 26 US: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 27 US: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 28 US: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 29 US: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2019-2032 (USD BILLION)
• TABLE 30 US: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 31 CANADA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 32 CANADA: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 33 CANADA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 34 CANADA: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2019-2032 (USD BILLION)
• TABLE 35 CANADA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 36 EUROPE: PEG 3350 MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
• TABLE 37 EUROPE: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 38 EUROPE: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 39 EUROPE: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 40 EUROPE: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 41 EUROPE: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 42 GERMANY: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 43 GERMANY: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 44 GERMANY: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 45 GERMANY: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 46 GERMANY: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 47 FRANCE: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 48 FRANCE: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 49 FRANCE: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 50 FRANCE: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 51 FRANCE: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 52 UK: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 53 UK: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 54 UK: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 55 UK: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2019-2032 (USD BILLION)
• TABLE 56 UK: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 57 ITALY: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 58 ITALY: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 59 ITALY: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 60 ITALY: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 61 ITALY: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 62 SPAIN: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 63 SPAIN: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 64 SPAIN: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 65 SPAIN: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 66 SPAIN: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 67 REST OF EUROPE: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 68 REST OF EUROPE: PEG 3350 MARKET, BY AGE, 2019-2032 (USD BILLION)
• TABLE 69 REST OF EUROPE: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 70 REST OF EUROPE: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 71 REST OF EUROPE: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 72 ASIA-PACIFIC: PEG 3350 MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
• TABLE 73 ASIA-PACIFIC: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 74 ASIA-PACIFIC: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 75 ASIA-PACIFIC: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 76 ASIA-PACIFIC: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 77 ASIA-PACIFIC: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 78 CHINA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 79 CHINA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 80 CHINA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 81 CHINA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 82 CHINA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 83 INDIA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 84 INDIA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 85 INDIA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 86 INDIA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 87 INDIA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 88 JAPAN: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 89 JAPAN: PEG 3350 MARKET, BY AGE, 2018-2030(USD BILLION) (USD BILLION)
• TABLE 90 JAPAN: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 91 JAPAN: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 92 JAPAN: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 93 SOUTH KOREA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 94 SOUTH KOREA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 95 SOUTH KOREA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 96 SOUTH KOREA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 97 SOUTH KOREA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 98 AUSTRALIA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 99 AUSTRALIA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 100 AUSTRALIA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 101 AUSTRALIA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 102 AUSTRALIA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 103 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 104 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 105 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 106 REST OF ASIA PACIFIC: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 107 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 108 REST OF THE WORLD: PEG 3350 MARKET, BY COUNTRY, 2018-2030 (USD BILLION)
• TABLE 109 REST OF THE WORLD: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 110 REST OF THE WORLD: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 111 REST OF THE WORLD: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 112 REST OF THE WORLD: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 113 REST OF THE WORLD: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 114 MIDDLE EAST: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 115 MIDDLE EAST: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 116 MIDDLE EAST: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 117 MIDDLE EAST: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 118 MIDDLE EAST: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 119 AFRICA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 120 AFRICA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 121 AFRICA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 122 AFRICA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 123 AFRICA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 124 LATIN AMERICA: PEG 3350 MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 125 LATIN AMERICA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD BILLION)
• TABLE 126 LATIN AMERICA: PEG 3350 MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 127 LATIN AMERICA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 128 LATIN AMERICA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
• TABLE 129 MAJOR PLAYERS IN THE GLOBAL PEG 3350 MARKET
• TABLE 130 MOST ACTIVE PLAYER IN THE GLOBAL PEG 3350 MARKET
• TABLE 131 PRODUCT LAUNCH/PRODUCT APPROVAL
• TABLE 132 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 133 LGM PHARMA: PRODUCTS/SERVICES OFFERED
• TABLE 134 MCKESSON CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 135 SISCO RESEARCH LABORATORIES PVT. LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 136 BASF SE: PRODUCTS/SERVICES OFFERED
• TABLE 137 MERCK KGAA: PRODUCTS OFFERED
• TABLE 138 BAYER AG: PRODUCTS OFFERED
• TABLE 139 BAYER AG: KEY DEVELOPMENTS
• TABLE 140 LUPIN PHARMACEUTICALS, INC.: PRODUCTS OFFERED
• TABLE 141 BRECKENRIDGE PHARMACEUTICAL, INC.: PRODUCTS OFFERED
• TABLE 142 PENDOPHARM: PRODUCTS OFFERED
• TABLE 143 PENDOPHARM: KEY DEVELOPMENTS

LIST OF FIGURES

• FIGURE 1 MARKET SYNOPSIS
• FIGURE 2 GLOBAL PEG 3350 MARKET
• FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
• FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL PEG 3350 MARKET
• FIGURE 5 DRIVER IMPACT ANALYSIS
• FIGURE 6 RESTRAINT IMPACT ANALYSIS
• FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL PEG 3350 MARKET
• FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PEG 3350 MARKET
• FIGURE 9 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE, 2022 & 2032 (USD BILLION)
• FIGURE 10 GLOBAL PEG 3350 MARKET, BY AGE, 2022 & 2032 (USD BILLION)
• FIGURE 11 GLOBAL PEG 3350 MARKET, BY APPLICATION, 2022 & 2032 (USD BILLION)
• FIGURE 12 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2032 (USD BILLION)
• FIGURE 13 GLOBAL: PEG 3350 MARKET, BY REGION 2022 & 2032 (USD BILLION)
• FIGURE 14 GLOBAL: PEG 3350 MARKET SHARE (%), BY REGION,
• FIGURE 15 NORTH AMERICA: PEG 3350 MARKET SHARE (%), BY COUNTRY
• FIGURE 16 EUROPE: PEG 3350 MARKET SHARE (%), BY COUNTRY,
• FIGURE 17 ASIA-PACIFIC: PEG 3350 MARKET SHARE (%), BY COUNTRY,
• FIGURE 18 REST OF THE WORLD: PEG 3350 MARKET SHARE (%), BY COUNTRY,
• FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS
• FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL PEG 3350 MARKET
• FIGURE 21 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 22 MCKESSON CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 23 MCKESSON CORPORATION: SWOT ANALYSIS
• FIGURE 24 BASF SE: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 25 BASF SE: SWOT ANALYSIS
• FIGURE 26 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 27 MERCK KGAA: SWOT ANALYSIS
• FIGURE 28 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 29 BAYER AG: SWOT ANALYSIS
• FIGURE 30 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 31 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS